Chronic Airway Disease
Conditions
Interventions
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Group 1: COPD Eligibility criteria are: (1) aged 40 years or older; (2) Admitted to the general ward of the respiratory department due to AECOPD as the main reason for admission. Group 2: Asthma Eligibility criteria are: (1) aged 18 years or older; (2) A patient admitted to the general respiratory ward with the main diagnosis of "acute exacerbation of bronchial asthma". Group 3 : Bronchiectasis Eligibility criteria are: (1) aged 18 years or older; (2) Admitted to the general ward of the Respiratory and Critical Care Medicine Department, hospitalized with acute exacerbation of bronchiectasis as the primary reason for admission.
Exclusion criteria
Exclusion criteria: Group 1: COPD The exclusion criteria are as follows: (1) Individuals who are unable to undergo pulmonary function tests during the expected stable period, such as those in tracheotomy status or long-term bed rest; (2) Expected survival period is less than one month; (3) Refusing to sign the informed consent form; (4) Participants who are currently participating in clinical trials or intervention studies of other drugs; (5) The researchers determined that acute exacerbation of chronic obstructive pulmonary disease was not the main reason for this hospitalization; Group 2: Asthma The exclusion criteria are as follows: (1) Refusing to sign the informed consent form; (2) Participants who are currently participating in clinical trials or intervention studies of other drugs; (3) Asthma like symptoms caused by EGPA and ABPA; (4) Expected to lose lung function in one month CT Patients undergoing blood collection and other examinations; (5) Pregnant women; Group 3 : Bronchiectasis The exclusion criteria are as follows: (1) The researchers concluded that acute exacerbation of bronchiectasis was not the main cause of hospitalization this time; (2) Cystic fibrosis associated bronchiectasis and traction bronchiectasis associated with interstitial lung disease or other lung diseases; (3) Active tuberculosis; (4) Individuals who are unable to undergo pulmonary function tests during the expected stable period, such as those in tracheotomy status or long-term bed rest; (5) If the expected survival period is less than one month (6), refuse to sign the informed consent form; (7) Participants who are currently participating in clinical trials or intervention studies of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of acute exacerbation of respiratory diseases, including the number of acute exacerbations, the number of hospitalizations due to acute exacerbations, and length of hospital stay; | — |
Secondary
| Measure | Time frame |
|---|---|
| Health related Quality of Life;Medical Cost;Cormorbidity;Drug use;Chest CT ;Complete Blood Count; | — |
Countries
China
Contacts
Public ContactYang Ting
China-Japan Friendship Hospital
Outcome results
None listed